- Deutivacaftor/tezacaftor/vanzacaftor approved for people with cystic fibrosis 6 years and older with at least one responsive mutation in the CFTR gene, including ...
However, people with other mutations in the CFTR gene, including those with variants that result in no proteins being made at all, cannot benefit from the drug. “Therefore, interest is being placed on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results